Aurora Cannabis Shifts to Medical-Only, Posts 7% Revenue Growth and 60% Margins
Aurora Cannabis expanded its internal GMP facilities in Canada and Germany, delivering CAD94 million in Q4 revenue (up 7% year-on-year) and generating global medical cannabis revenue of CAD212 million, up from CAD177 million. The company pivoted to medical-only operations, achieving mid-to-high 60% margins and securing a $100 million ATM facility.
1. Strategic Pivot to Medical-Only
Aurora has shifted its focus solely to medical cannabis, exiting lower-margin consumer and plant propagation segments to streamline operations and improve profitability.
2. Financial Performance and Margin Improvement
The company reported CAD94 million in quarterly revenue, marking 7% year-on-year growth, and CAD212 million in global medical cannabis revenue year-to-date, driven by operational efficiencies that delivered mid-to-high 60% gross margins.
3. International Expansion and Capacity Investments
Aurora is expanding its internal GMP manufacturing capacity in Canada and Germany, holds one of three domestic cultivation licenses in Germany, and is optimizing its Australian portfolio and partnerships to target higher-margin medical markets.
4. Consumer Scale-Back and Strategic Funding
The company is rationalizing consumer SKUs and divesting its plant propagation unit to reduce cost pressure, anticipates one-time transition costs before improved adjusted EBITDA margins, and has established a $100 million at-the-market facility for accretive growth initiatives.